Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration

David S Alberts, E. A. Surwit, Y. M. Pen, T. McCloskey, R. Rivest, V. Graham, L. McDonald, Denise Roe

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

On the basis of its high degree of cytotoxicity against fresh human ovarian cancers and its relative lack of vesicant activity, mitoxantrone administered by the i.p. route was studied in a Phase I and pharmacokinetic trial. Thirty-three patients with good performance status and diagnoses of metastatic or recurrent ovarian (31 patients) and colon (two patients) cancers were treated with 12- to 38-mg/m2 doses, administered by the i.p. route every 4 wk for up to ten treatment courses. Mitoxantrone doses were escalated at 2- to 3-mg/m2 increments in groups of three to 11 patients. Thirty-eight mg/m2 (by i.p. dwell without removal) were considered the maximally tolerated dose in that, of eight treated patients, four experienced severe leukopenia and six experienced severe abdominal pain. Response to i.p. mitoxantrone was evaluable in 17 patients. None of seven patients with clinically measurable intraabdominal or pelvic tumor masses responded; however, in three (50%) of six patients with nonmeasurable disease, there was normalization of previously elevated serum CA-125 concentrations for 3, 17, and 24 mo. Additionally, two (50%) of four patients who underwent third-look laparotomies were found to have >75% reductions in i.p. tumor masses with response lasting 24 and 25 mo. At 38 mg/m2, mitoxantrone was associated with a mean concentration·time product of 100 μg·h/ml in the i.p. space and of 0.071 μg·h/ml in plasma, yielding an i.p./plasma area under the curve ratio of 1408. We conclude that chemical peritonitis is the dose-limiting toxicity of i.p. administered mitoxantrone and that a dose of 23 mg/m2 every 3 to 4 wk should be used in future Phase II trials in ovarian cancer patients with minimal residual intraabdominal and pelvic disease following second-look laparotomy.

Original languageEnglish (US)
Pages (from-to)5874-5877
Number of pages4
JournalCancer Research
Volume48
Issue number20
StatePublished - 1988

Fingerprint

Mitoxantrone
Pharmacokinetics
Ovarian Neoplasms
Laparotomy
Clinical Studies
Neoplasms
Maximum Tolerated Dose
Irritants
Leukopenia
Peritonitis
Abdominal Pain
Area Under Curve
Colon

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. / Alberts, David S; Surwit, E. A.; Pen, Y. M.; McCloskey, T.; Rivest, R.; Graham, V.; McDonald, L.; Roe, Denise.

In: Cancer Research, Vol. 48, No. 20, 1988, p. 5874-5877.

Research output: Contribution to journalArticle

Alberts, DS, Surwit, EA, Pen, YM, McCloskey, T, Rivest, R, Graham, V, McDonald, L & Roe, D 1988, 'Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration', Cancer Research, vol. 48, no. 20, pp. 5874-5877.
Alberts, David S ; Surwit, E. A. ; Pen, Y. M. ; McCloskey, T. ; Rivest, R. ; Graham, V. ; McDonald, L. ; Roe, Denise. / Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. In: Cancer Research. 1988 ; Vol. 48, No. 20. pp. 5874-5877.
@article{d21d91c0c83345a2a802cb8f5a8ed54b,
title = "Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration",
abstract = "On the basis of its high degree of cytotoxicity against fresh human ovarian cancers and its relative lack of vesicant activity, mitoxantrone administered by the i.p. route was studied in a Phase I and pharmacokinetic trial. Thirty-three patients with good performance status and diagnoses of metastatic or recurrent ovarian (31 patients) and colon (two patients) cancers were treated with 12- to 38-mg/m2 doses, administered by the i.p. route every 4 wk for up to ten treatment courses. Mitoxantrone doses were escalated at 2- to 3-mg/m2 increments in groups of three to 11 patients. Thirty-eight mg/m2 (by i.p. dwell without removal) were considered the maximally tolerated dose in that, of eight treated patients, four experienced severe leukopenia and six experienced severe abdominal pain. Response to i.p. mitoxantrone was evaluable in 17 patients. None of seven patients with clinically measurable intraabdominal or pelvic tumor masses responded; however, in three (50{\%}) of six patients with nonmeasurable disease, there was normalization of previously elevated serum CA-125 concentrations for 3, 17, and 24 mo. Additionally, two (50{\%}) of four patients who underwent third-look laparotomies were found to have >75{\%} reductions in i.p. tumor masses with response lasting 24 and 25 mo. At 38 mg/m2, mitoxantrone was associated with a mean concentration·time product of 100 μg·h/ml in the i.p. space and of 0.071 μg·h/ml in plasma, yielding an i.p./plasma area under the curve ratio of 1408. We conclude that chemical peritonitis is the dose-limiting toxicity of i.p. administered mitoxantrone and that a dose of 23 mg/m2 every 3 to 4 wk should be used in future Phase II trials in ovarian cancer patients with minimal residual intraabdominal and pelvic disease following second-look laparotomy.",
author = "Alberts, {David S} and Surwit, {E. A.} and Pen, {Y. M.} and T. McCloskey and R. Rivest and V. Graham and L. McDonald and Denise Roe",
year = "1988",
language = "English (US)",
volume = "48",
pages = "5874--5877",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration

AU - Alberts, David S

AU - Surwit, E. A.

AU - Pen, Y. M.

AU - McCloskey, T.

AU - Rivest, R.

AU - Graham, V.

AU - McDonald, L.

AU - Roe, Denise

PY - 1988

Y1 - 1988

N2 - On the basis of its high degree of cytotoxicity against fresh human ovarian cancers and its relative lack of vesicant activity, mitoxantrone administered by the i.p. route was studied in a Phase I and pharmacokinetic trial. Thirty-three patients with good performance status and diagnoses of metastatic or recurrent ovarian (31 patients) and colon (two patients) cancers were treated with 12- to 38-mg/m2 doses, administered by the i.p. route every 4 wk for up to ten treatment courses. Mitoxantrone doses were escalated at 2- to 3-mg/m2 increments in groups of three to 11 patients. Thirty-eight mg/m2 (by i.p. dwell without removal) were considered the maximally tolerated dose in that, of eight treated patients, four experienced severe leukopenia and six experienced severe abdominal pain. Response to i.p. mitoxantrone was evaluable in 17 patients. None of seven patients with clinically measurable intraabdominal or pelvic tumor masses responded; however, in three (50%) of six patients with nonmeasurable disease, there was normalization of previously elevated serum CA-125 concentrations for 3, 17, and 24 mo. Additionally, two (50%) of four patients who underwent third-look laparotomies were found to have >75% reductions in i.p. tumor masses with response lasting 24 and 25 mo. At 38 mg/m2, mitoxantrone was associated with a mean concentration·time product of 100 μg·h/ml in the i.p. space and of 0.071 μg·h/ml in plasma, yielding an i.p./plasma area under the curve ratio of 1408. We conclude that chemical peritonitis is the dose-limiting toxicity of i.p. administered mitoxantrone and that a dose of 23 mg/m2 every 3 to 4 wk should be used in future Phase II trials in ovarian cancer patients with minimal residual intraabdominal and pelvic disease following second-look laparotomy.

AB - On the basis of its high degree of cytotoxicity against fresh human ovarian cancers and its relative lack of vesicant activity, mitoxantrone administered by the i.p. route was studied in a Phase I and pharmacokinetic trial. Thirty-three patients with good performance status and diagnoses of metastatic or recurrent ovarian (31 patients) and colon (two patients) cancers were treated with 12- to 38-mg/m2 doses, administered by the i.p. route every 4 wk for up to ten treatment courses. Mitoxantrone doses were escalated at 2- to 3-mg/m2 increments in groups of three to 11 patients. Thirty-eight mg/m2 (by i.p. dwell without removal) were considered the maximally tolerated dose in that, of eight treated patients, four experienced severe leukopenia and six experienced severe abdominal pain. Response to i.p. mitoxantrone was evaluable in 17 patients. None of seven patients with clinically measurable intraabdominal or pelvic tumor masses responded; however, in three (50%) of six patients with nonmeasurable disease, there was normalization of previously elevated serum CA-125 concentrations for 3, 17, and 24 mo. Additionally, two (50%) of four patients who underwent third-look laparotomies were found to have >75% reductions in i.p. tumor masses with response lasting 24 and 25 mo. At 38 mg/m2, mitoxantrone was associated with a mean concentration·time product of 100 μg·h/ml in the i.p. space and of 0.071 μg·h/ml in plasma, yielding an i.p./plasma area under the curve ratio of 1408. We conclude that chemical peritonitis is the dose-limiting toxicity of i.p. administered mitoxantrone and that a dose of 23 mg/m2 every 3 to 4 wk should be used in future Phase II trials in ovarian cancer patients with minimal residual intraabdominal and pelvic disease following second-look laparotomy.

UR - http://www.scopus.com/inward/record.url?scp=0023753617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023753617&partnerID=8YFLogxK

M3 - Article

C2 - 3167842

AN - SCOPUS:0023753617

VL - 48

SP - 5874

EP - 5877

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 20

ER -